Smoldering multiple myeloma
Drug research and approvals for smoldering multiple myeloma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 32 studies of smoldering multiple myeloma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 32
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its…NCT07446777 · Not applicable · University of Miami · starts Apr 7, 2026
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)NCT07393282 · Phase 3 · Regeneron Pharmaceuticals · starts May 21, 2026
- Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical EvolutionNCT07214324 · Not reported · Azienda USL Reggio Emilia - IRCCS · starts Mar 17, 2025
- A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in…NCT07069751 · Not applicable · Ciceri Fabio · starts Oct 31, 2025
- Whole Body MRI in OncologyNCT06895291 · Not reported · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · starts Oct 26, 2023
- A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for…NCT06768489 · Phase 1 · Janssen Research & Development, LLC · starts Dec 4, 2024
- Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaNCT06762769 · Phase 2 · University College, London · starts Jun 2, 2025
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple MyelomaNCT06745687 · Not applicable · Institute of Hematology & Blood Diseases Hospital, China · starts Dec 30, 2024
- CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot StudyNCT06644625 · Not reported · Wake Forest University Health Sciences · starts Mar 1, 2025
Phase 3 4
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- Hyaluronidase (human recombinant)Hyaluronic acid hydrolytic enzyme
Phase 2 8
- LeflunomideDihydroorotate dehydrogenase inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- ElranatamabT cell surface glycoprotein CD3 binding agent
- Carfilzomib26S proteasome inhibitor
- CholestyramineBile acids sequestering agent
- ElotuzumabSLAM family member 7 inhibitor
- IsatuximabLymphocyte differentiation antigen CD38 inhibitor
- IberdomideCRL4(CRBN) E3 ubiquitin ligase modulator
Phase 1 or earlier 3
- AnakinraInterleukin-1 receptor antagonist
- Bortezomib26S proteasome inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
How its trials ended
97 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 22 whose ending is known, 18% met their primary endpoint, 0% missed it and 82% stopped early.
- Ongoing5557%
- Completed, result not reported1718%
- Stopped: other or unclear1010%
- Met its primary endpoint44%
- Stopped: enrollment or feasibility44%
- Status unknown33%
- Stopped: sponsor or business decision22%
- Stopped: lack of efficacy11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA